查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268937

2023-2030 年口腔粘膜劑的全球市場

Global Oral Transmucosal Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球口腔粘膜劑市場預計將出現有利可圖的增長，到 2022 年將達到 150.52 億美元，到 2030 年將達到 244.414 億美元。 預計在預測期內（2023-2030 年），口腔粘膜市場的複合年增長率為 6.4%。

在全球範圍內，慢性或非傳染性疾病呈上升趨勢，佔所有死亡人數的 73%。 在印度，非傳染性疾病造成了 44% 的傷殘調整生命年損失和 53% 的死亡。 印度擁有世界六分之一以上的人口，其高度發達的社會經濟和慢性非傳染性疾病的流行病學趨勢導致口服藥物市場增長加快。

2019 年冠狀病毒病 (COVID-19) 大流行大大增加了臨終和姑息治療對替代給藥途徑的需求，尤其是在社區環境中。 經粘膜途徑包括鼻內、口腔、舌下和直腸。 這些途徑可以自我給藥或由家庭護理人員給藥，並且是全身給藥的非侵入性途徑。 自身免疫性疾病病例上升、技術進步和市場開發等因素正在推動全球經口粘膜市場的增長。

市場動態

自身免疫性疾病和癌症發病率上升推動市場增長

例如，美國癌症協會每年都會估計美國的新癌症病例和死亡人數，並彙編有關基於人群的癌症發病率和結果的最新數據。 2022 年，美國將有 1,918,030 例新癌症病例和 609,360 例癌症死亡病例，其中肺癌是癌症的首要原因，每天約有 350 例死亡。我在這裡。 因此，癌症的流行正在推動市場的增長。

透粘膜藥物的技術問題

經粘膜給藥優於口服和腸胃外劑型，因為它是非侵入性的，可以自行給藥或由經過培訓的護理人員給藥。 要找到適合經粘膜給藥的藥物，重要的是要了解粘膜藥物吸收的機制。 雖然鼻腔、口腔和直腸粘膜各有獨特的形態和生理特徵，但它們也有一些共同點。

COVID-19 影響分析

由於供應鏈中斷、政府封鎖、勞動力短缺和製造活動限制，COVID-19 大流行對口服藥物市場產生了短期的負面影響。 與此同時，口服藥物製造商正受益於冠狀病毒的爆發，首過代謝降低，起效更快。 由於這些特性，口服藥物可用於姑息治療和臨終關懷以快速緩解症狀。 在 COVID-19 大流行期間，這是強制性的，因為在某些情況下，患者的健康狀況往往會迅速惡化。

俄烏衝突分析

俄羅斯和烏克蘭由於滲透率低且缺乏主要市場參與者，估計對全球經口粘膜劑市場的影響不大。 但預計原材料進出口的影響在預測期內對全球口腔粘膜市場影響不大。

人工智能影響分析

人工智能 (AI) 在社會的許多領域無處不在，尤其是在製藥行業。 人工神經網絡 (ANN)、信息技術和無線通信都在幫助開發智能藥物輸送系統，這些系統有可能克服傳統療法的缺點。 通過無線連接，用於受監管藥物分配的設備變得更加通用。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按產品類型分類的摘要
  • 按指示摘錄
  • 按給藥途徑分類的片段
  • 按分發渠道分類的摘要
  • 區域摘要

第四章市場動態

  • 影響因素
    • 司機
      • 自身免疫性疾病、呼吸系統疾病和癌症的發病率上升推動了市場增長
      • 藥物治療/增加藥物治療的使用
    • 約束因素
      • 與透粘膜藥物相關的監管問題
    • 機會
      • 啟動研發活動
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏戰爭分析

第八章全球經濟衰退分析

第9章人工智能的影響分析

第 10 章按產品類型

  • 藥丸
  • 電影
  • 液體/噴霧
  • 其他

第11章適應症

  • 阿片成癮
  • 神經系統疾病
  • 勃起功能障礙
  • 噁心和嘔吐
  • 其他

第12章給藥途徑

  • 舌下粘膜
  • 頰粘膜
  • 其他

第 13 章分銷渠道

  • 零售藥房
  • 醫院藥房
  • 在線藥店

第14章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第15章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十六章公司簡介

  • 輝瑞公司
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • ZIM Laboratories Limited
  • Aquestive Therapeutics, Inc
  • IntelGenx Corp
  • Indivior PLC
  • C.L.Pharm Co., Ltd
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals, Inc
  • CURE Pharmaceutical.

第17章 附錄

簡介目錄
Product Code: PH4314

Market Overview

The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.

The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.

Market Dynamics

Increase in the incidence of autoimmune disorders and cancer to boost the market growth

For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.

Technical challenges of transmucosal drug

Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.

COVID-19 Impact Analysis

Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.

For more details on this report - Request for Sample

Segment Analysis

The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.

The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.

The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.

Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.

The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.

For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.

Competitive Landscape

The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.

Why Purchase the Report?

  • To visualize the global oral transmucosal drugs market segmentation based on product, application, and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
      • 4.1.1.2. The increase in medication and pharmacological therapy usage
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory challenges for transmucosal drug
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of research and developments activities
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Tablets
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Films
  • 10.4. Liquids & Spray
  • 10.5. Others

11. By Indication

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Opioid Dependence *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Neurological Disorders
  • 11.4. Erectile Dysfunction
  • 11.5. Nausea and Vomiting
  • 11.6. Others

12. By Route of Administration

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.1.2. Market Attractiveness Index, By Route of Administration
  • 12.2. Sublingual Mucosa *
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Buccal Mucosa
  • 12.4. Others

13. By Distribution Channel

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.1.2. Market Attractiveness Index, By Distribution Channel
  • 13.2. Retail Pharmacies*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Hospital Pharmacies
  • 13.4. Online Pharmacies

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Pfizer Inc.*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. ZIM Laboratories Limited
  • 16.3. Aquestive Therapeutics, Inc
  • 16.4. IntelGenx Corp
  • 16.5. Indivior PLC
  • 16.6. C.L.Pharm Co., Ltd
  • 16.7. Seoul Pharmaceuticals
  • 16.8. Shilpa Therapeutics
  • 16.9. Sunovion Pharmaceuticals, Inc
  • 16.10. CURE Pharmaceutical.

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us